On March 18, 2026, analyst Patrick R. Trucchio, CFA, of H.C. Wainwright & Co. reiterated a Buy rating and US$50 price target on Alto Neuroscience Inc. (ANRO:NYSE), following the company's fourth-quarter 2025 earnings report.
The note highlighted Alto's entry into a catalyst-rich 2026, with multiple top-line data readouts expected across its late-stage precision neuropsychiatry pipeline. At the time of publication, shares traded at US$22.45, implying approximately 123% upside to the price target.
Financial Position and Fundraising
As of December 31, 2025, Alto reported cash and cash equivalents of US$177 million, slightly above H.C. Wainwright's prior estimate of US$174 million, with the variance attributed to lower-than-expected operating expenses. The company expects this cash runway to fund planned operations into 2028, covering key data readouts.
Additionally, on March 16, Alto raised US$120 million through a private placement financing, bringing expected pro forma cash to approximately US$275 million. The additional capital is intended to support the development of ALTO-207 in treatment-resistant depression through a Phase 3 trial expected to begin in early 2027 and potentially through to a new drug application submission.
ALTO-207: Treatment-Resistant Depression
ALTO-207 is a fixed-dose combination of pramipexole (a dopamine D3-preferring D3/D2 agonist) and ondansetron (a 5-HT3 antagonist) being developed for treatment-resistant depression (TRD). A Phase 2b trial is on track to initiate in the first half of 2026 and is described as potentially pivotal in design. The study is expected to be a randomized, double-blind, placebo-controlled trial evaluating ALTO-207 as an adjunctive treatment in approximately 178 adults with TRD.
Participants will be randomized 1:1 to receive ALTO-207 or placebo during an eight-week double-blind treatment period, with the primary endpoint being change from baseline in MADRS. Top-line data from this trial is expected in the second half of 2027.
The program is supported by prior clinical evidence, including the PAX-D study conducted by the University of Oxford showing a Cohen's d of 0.87, a meta-analysis demonstrating a significant Hedges' g effect size of 0.64 (p<0.001) across randomized pramipexole trials, and data from a Phase 2a trial demonstrating a statistically significant and clinically meaningful placebo-adjusted 8.2-point mean reduction in MADRS at Week 8 (n=32; p=0.025; Cohen's d=1.1). On a risk-adjusted basis, H.C. Wainwright estimates ALTO-207 is worth US$25 per share. Alto also strengthened its intellectual property position on January 14, with patent claims expected to extend into the mid-2040s.
ALTO-101: Cognitive Impairment in Schizophrenia
On February 13, Alto announced complete enrollment for its Phase 2 trial evaluating ALTO-101, a transdermal PDE4 inhibitor with Fast Track designation, in cognitive impairment associated with schizophrenia (CIAS). The trial enrolled 83 patients across 13 U.S. clinical sites and is designed as a randomized, double-blind, placebo-controlled crossover study with a primary endpoint of theta-band inter-trial coherence (theta-ITC) on EEG. Top-line data is expected around the first quarter of 2026.
The program was further de-risked by data presented at the Annual Meeting of the American College of Neuropsychopharmacology (ACNP) on January 12–15, where an independent data set of 427 individuals (155 with schizophrenia; 272 healthy controls) validated prior findings supporting theta-ITC as the most robust EEG marker for detecting case-control differences. This represented the second large independent replication. While H.C. Wainwright does not currently assign a value to ALTO-101 pending clinical data, the firm views it as a potentially first-in-class, biomarker-guided treatment in CIAS.
ALTO-300: Major Depressive Disorder
ALTO-300 (agomelatine 25 mg) is an oral melatonergic agonist and 5-HT2C antagonist currently in a randomized, double-blind, placebo-controlled Phase 2b trial (n≈200) as an adjunctive treatment for major depressive disorder (MDD). The study enrolls biomarker-positive patients identified by EEG signals indicating increased neural noise and reduced dopaminergic activity. Phase 2b top-line data is expected in mid-2026. H.C. Wainwright views ALTO-300 as a well-differentiated, biomarker-guided adjunctive therapy with a safety advantage over existing atypical antipsychotic adjuncts. On an unadjusted basis, the firm estimates ALTO-300 may generate peak annual revenues of US$2.5 billion or more in MDD. Risk-adjusted, ALTO-300 is estimated to be worth US$20 per share.
ALTO-100: Bipolar Depression
ALTO-100 is a first-in-class small molecule that enhances neuroplasticity via BDNF pathway modulation. It is currently being evaluated for bipolar depression (BPD) in an ongoing Phase 2b trial (n≈200) targeting patients with cognitive biomarkers associated with chronicity and treatment resistance.
The trial includes a 6-week treatment phase and a 7-week open-label extension, with top-line data expected in the second half of 2026. On an unadjusted basis, H.C. Wainwright estimates ALTO-100 may generate peak annual revenues of US$1 billion or more in BPD. Risk-adjusted, ALTO-100 is estimated to be worth US$3 per share.
Precision Psychiatry Thesis
H.C. Wainwright highlighted a recent key opinion leader webinar hosted by Denovo Neuroscience as validation of the potential for precision psychiatry to disrupt the treatment landscape. The event laid out the central nervous system "tax" framework—the structural trial failures driven by high placebo responses and rater variability—that Alto's platform is designed to bypass. By using EEG- and neurobiology-driven enrichment to select patients before trial enrollment, Alto aims to increase signal detection and de-risk the late-stage attrition that has historically plagued CNS drug development. The firm views Alto's focus on biomarker-guided oral therapies as offering a scalable model that can reach a broader population through routine care settings, in contrast to interventional psychiatry approaches that are limited by capacity and specialized clinic requirements.
Valuation and Risks
H.C. Wainwright values Alto using a sum-of-the-parts and risk-adjusted discounted cash flow methodology. The firm assigns probabilities of success of 30% to ALTO-300 in MDD, 30% to ALTO-207 in TRD, and 10% to ALTO-100 in BPD. The model incorporates annual equity raises of US$150 million from 2027 through 2029 to fund clinical development and potential commercial launch, a 12% discount rate, and a 6x terminal multiple. These assumptions yield a total firm value of approximately US$2 billion, supporting the US$50 price target.
Key risks identified include clinical development risk across the pipeline, execution and trial quality risk, biomarker regulatory acceptance risk, commercial adoption risk tied to EEG-based diagnostics, financing and dilution risk given the early stage of pipeline monetization, and platform risk if biomarkers fail to consistently predict clinical response across programs. The firm does not expect revenue generation until 2028, with estimated product revenues of US$18.6 million that year, growing to US$338.5 million by 2031. GAAP EPS is estimated at negative US$2.75 for 2026 and negative US$3.44 for 2027, with profitability projected in 2031 at US$0.95 per share.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Alto Neuroscience Inc.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
Disclosures for H.C. Wainwright & Co., Alto Neuroscience Inc., March 18, 2026
This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet. H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility. RETURN ASSESSMENT Market Outperform (Buy): The common stock of the company is expected to outperform a passive index comprised of all the common stock of companies within the same sector. Market Perform (Neutral): The common stock of the company is expected to mimic the performance of a passive index comprised of all the common stock of companies within the same sector. Market Underperform (Sell): The common stock of the company is expected to underperform a passive index comprised of all the common stock of companies within the same sector. Rating and Price Target History for: Alto Neuroscience, Inc. (ANRO-US) as of 03-16-2026 25 20 15 10 5 0 2023 Q1 Q2 Q3 2024 Q1 Q2 Q3 2025 Q1 Q2 Q3 2026 Q1 I:BUY:$10.00 04/07/25 BUY:$50.00 10/24/25 Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months. Distribution of Ratings Table as of March 16, 2026 IB Service/Past 12 Months Ratings Count Percent Count Percent Buy 584 87.03% 159 27.23% Neutral 62 9.24% 11 17.74% Sell 1 0.15% 0 0.00% Under Review 24 3.58% 4 16.67% H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Patrick R. Trucchio, CFA , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Alto Neuroscience, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of February 28, 2026 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Alto Neuroscience, Inc.. Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from Alto Neuroscience, Inc. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from Alto Neuroscience, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Alto Neuroscience, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.
